FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
Keyword: detection
Relevance: High
Strength of Science: Medium-High
Research Timeline: Human Research
View Related Clinical TrialsStudy : Prostate cancer screening may benefit people with Lynch syndrome
Relevance: High
Strength of Science: Medium-High
Research Timeline: Human Research
View Related Clinical TrialsMost relevant for: People with Lynch syndrome
Initial results from the IMPACT trial show that PSA testing to screen for prostate cancer in people with Lynch syndrome can detect aggressive early prostate cancers. These findings support the use of PSA screening in men with Lynch syndrome, particularly men with an inherited mutation in an MSH2 or MSH6 gene. (Posted 11/10/22)
Este artículo está disponible en español.
Read MoreRelevance: High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Screening for pancreatic cancer detects early-stage disease and improves survival
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: People at increased risk for pancreatic cancer because of family history or an inherited mutation.
A research study has shown that screening for pancreatic cancer in people with an inherited mutation or family history was able to detect early-stage pancreatic cancers and improve survival. These results will likely change pancreatic cancer screening guidelines for high-risk individuals (Posted 8/30/22)
Este artículo está disponible en español.
Read MoreRelevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : The chance of a second breast cancer is higher among some Hawai'ian women
Relevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: women of Hawai’ian, Filipino or Asian American ancestry.
Women diagnosed with ductal carcinoma in situ (DCIS), an early form of breast cancer, are more likely to have a second breast cancer diagnosis if they are of Native Hawai'ian, Filipino or Japanese ancestry than women of other racial or ethnic groups. (posted 3/15/22)
Este artículo está disponible en español.
Read MoreUpdate : Blood tests called liquid biopsies for cancer screening, monitoring and treatment
Most relevant for: People considering a liquid biopsy to screen for cancer
Could a simple blood test change cancer detection, treatment and monitoring? Several companies are offering a type of blood test known as a liquid biopsy to detect multiple cancers at their earliest stages, monitor response to treatment and help choose the best treatment. Although progress has been made using liquid biopsies to treat cancer, these tests have not yet been shown to detect cancer early enough to save lives. (posted 9/29/21)
Este artículo está disponible en español.
Read MoreRelevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
Study : Expanded access to Medicaid coverage under the Affordable Care Act is linked to reduced cancer mortality
Relevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
Most relevant for: People with breast, colorectal or lung cancer.
In 2014 the Affordable Care Act expanded Medicaid coverage. How did this affect healthcare for cancer patients? This study shows that deaths from breast, colorectal and lung cancer are lower in states that chose to expand Medicaid compared to states that did not. Early diagnosis was linked to lower death rates. This suggests that increased healthcare access may lead to earlier cancer detection and better outcomes, including lower mortality. (3/31/2021)
Este artículo está disponible en español.
Read MoreRelevance: High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Immunotherapy drug Keytruda received FDA approval and showed benefit for treatment of colorectal cancer
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: People with advanced colorectal cancer and a type of biomarker called MSI-High (MSI-H)
In June 2020, the FDA approved Keytruda (pembrolizumab) as an initial therapy for advanced colorectal cancer. This approval was based on the results from the KEYNOTE-177 study. In this study, Keytruda was more successful than chemotherapy in delaying progression of certain types of colorectal cancers. (11/25/20)
Read MoreRelevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Knowing about an inherited BRCA mutation improves outcomes for women with breast cancer
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: Young women with, or at high risk for an inherited BRCA mutation
Inherited mutations in the BRCA1 and BRCA2 genes are linked to a high lifetime risk of breast and other cancers. This study shows that women who know that they have a BRCA mutation before they are diagnosed with breast cancer have improved outcomes including diagnosis at earlier stages and improved overall survival. (10/26/20)
Read MoreRelevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
View Related Clinical TrialsStudy : A new blood test may help predict early-stage breast cancer patients at highest risk for recurrence
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
View Related Clinical TrialsMost relevant for: People with early-stage breast cancer
Which patients are at risk for a relapse of early-stage breast cancer? Tests to predict recurrence would help find people who need more monitoring after treatment and provide a chance to find and treat them earlier. This study looked at whether a blood test for tumor DNA (called circulating tumor DNA or ctDNA) is useful for finding people with recurrence earlier than current clinical practice. (11/4/19)
Este artículo está disponible en español.
Read MoreRelevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : MRI or mammograms for detecting breast cancer in families with unknown genetic mutations?
Relevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: People with a personal or family history of cancer where no mutation has been found
MRI and mammograms are used together to detect breast cancer in high-risk women who test positive for a BRCA or other gene mutation that increases the risk for breast cancer. For women with a family history of breast cancer but no known genetic mutation, increased screening is recommended. But what method is best? A recent clinical trial in the Netherlands compared MRI and mammography for this population. (8/15/19)
Read MoreRelevance: Medium-High
Strength of Science: Medium-High
Study : Diagnosis and treatment delays in young women with breast cancer
Relevance: Medium-High
Strength of Science: Medium-High
Most relevant for: Young women who find a breast lump and young women newly-diagnosed with breast cancer
Young women are more likely to have delays in a breast cancer diagnosis and treatment. Factors that affect these delays include pregnancy, breastfeeding, financial concerns and having a family history of breast or ovarian cancer. (8/5/19)
Este artículo está disponible en español.
Read More